Rituximab for treating inhibitors in people with inherited severe hemophilia (Q24186623)

Europe PubMed Central

title

Rituximab for treating inhibitors in people with inherited severe hemophilia (English)

0 references

0 references

1 reference

Yi Liu

1

0 references

Lingli Zhang

2

0 references

Cristina Santoro

3

0 references

Jie Song

4

0 references

Armando Rodriguez

5

0 references

Li Wang

Cochrane Database of Systematic Reviews

6

0 references

publication date

4 April 2015

0 references

published in

0 references

cites work

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

International workshop on immune tolerance induction: consensus recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

Rituximab for adolescents with haemophilia and high titre inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

Treatment with rituximab in benign and malignant hematologic disorders in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

Factor VIII products and inhibitor development in severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

The principal results of the International Immune Tolerance Study: a randomized dose comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

Rituximab in the treatment of high responding inhibitors in severe haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

Rituximab therapy for juvenile-onset systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Successful suppression using Rituximab of a factor VIII inhibitor in a boy with severe congenital haemophilia: an example of a significant decrease of treatment costs

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Meta-analyses involving cross-over trials: methodological issues

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010810.PUB2